Updates are available Correction dated 2025-03-18
Click to view Correction: https://doi.org/10.1038/s41537-025-00595-0
-
Authors
Kaul, Inder
Sawchak, Sharon
Claxton, Amy
Sauder, Colin
Hassman, Howard H.
Kakar, Rishi
Walling, David P. https://orcid.org/0000-0001-8638-2086
Citrome, Leslie https://orcid.org/0000-0002-6098-9266
Zhu, Haiyuan https://orcid.org/0009-0007-0903-9349
Miller, Andrew C.
Brannan, Stephen K. https://orcid.org/0000-0003-0922-5970
-
Funding
Funding for this research was provided by:
Karuna Therapeutics, a Bristol Myers Squibb Company
- License Information
-
More Information
Article History
Received: 23 May 2024
Accepted: 9 October 2024
First Online: 2 November 2024
Change Date: 18 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41537-025-00595-0
Competing interests
: I.K., S.S., A.C., C.S., and H.Z. are employees of Karuna Therapeutics, a Bristol Myers Squibb company. A.C.M and S.K.B. are consultants of Karuna Therapeutics, a Bristol Myers Squibb company. H.H.H. was a principal investigator for the EMERGENT-1 and EMERGENT-2 trials. R.K. was a principal investigator for the EMERGENT-2 trial. L.C. is a consultant for AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo/Sunovion, Supernus, Teva, University of Arizona, Vanda, Wells Fargo, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research; is a speaker for AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and universities and professional organizations/societies; owns stocks (small number of shares of common stock) in Bristol-Myers Squibb, Eli Lilly, J & J, Merck, and Pfizer purchased >10 years ago, and stock options: Reviva; receives royalties/publishing income from Taylor & Francis (Editor-in-Chief, Current Medical Research and Opinion, 2022-date), Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics). D.P.W. has received research support from AbbVie, Acadia, Alkermes, Allergan, Avanir, BMS, Cerevel, Indivior, IntraCellular, J & J RPD, Karuna, Lupin, Lundbeck, Neurocrine, Novartis, Noven, Pfizer, Roche, Sage, Sunovion, and Takeda; and has received research support and served as a consultant for Biogen, Boehringer Ingelheim, Janssen, Lyndra, and Otsuka.
